Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use
NCT04627922Phase 4Completed
- Start
- Aug 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Tobacco Use Disorder (TUD) and cannabis use disorder (CUD) comparing N-acetyl cysteine (NAC) & cognitive behavioral therapy with Placebo & cognitive behavioral therapy (2 arms). Primary endpoints: Change in the Mean Days of Cannabis Use Over Time at 12 weeks, Change in the Mean Number of Cigarettes Used Over Time at 12 weeks and 7 more. Started Aug 2021; status: completed.
02
Drugs
acetylcysteine
03
Conditions
Tobacco Use Disorder (TUD)cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT04627922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627922.